Supplementary Table. Safety of One Dose of Moderna mResvia Respiratory Syncytial Virus Vaccine in Adults Aged ≥60 Years — Phase 1 and 2/3 Pivotal Efficacy Trials, Multiple Countries, 2021–2024

Details

• Alternative Title:
  Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024: Supplementary Table. Safety of One Dose of Moderna mResvia Respiratory Syncytial Virus Vaccine in Adults Aged ≥60 Years — Phase 1 and 2/3 Pivotal Efficacy Trials, Multiple Countries, 2021–2024
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Supplementary Material - Morbidity and mortality weekly report 2024-73-32
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 32
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Statistics ; Tables
• Genre:
  Tables ; Statistics
• Pages in Document:
  1 pdf page
• Volume:
  73
• Issue:
  32
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:95c14c65ce93c75e7e787a09726d4e020e48bc8fb17c84ce73335fa97337f26d9a59123d0b3cbc91dd872c7f403f93bd1f2a25d183cb304ed875f7b871c3badf
• Download URL:
  https://stacks.cdc.gov/view/cdc/159161/cdc_159161_DS1.pdf
• File Type:
  [PDF - 131.27 KB ]